Monthly Prescribing Reference

Long-Acting Octreotide Therapy Gets Orphan Drug Status for Polycystic Liver Disease

CAM2029 is an investigational ready-to-use, long-acting octreotide subcutaneous injection depot. Polycystic liver disease is a rare genetic disorder characterized by the progressive growth of more ...
Nasdaq

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.

PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of the first and ...
FiercePharma

Phase III Novartis data show potential benefit of Afinitor® plus Sandostatin® LAR® in patients with advanced neuroendocrine tumo

Everolimus plus octreotide LAR extended time without tumor growth from 11.3 to 16.4 months versus octreotide LAR alone in advanced NET (carcinoid) patients[1] The study did not reach its primary ...
ascopubs.org

A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors

Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia Randomized, single-blinded study. Patients with NETs received ...
Healio

Oral octreotide associated with better quality of life, work productivity in acromegaly

Please provide your email address to receive an email when new articles are posted on . Adults with acromegaly reported improved quality of life and more work productivity after transitioning from ...
Nasdaq

Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients

Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1≤1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom ...
Monthly Prescribing Reference

Presence of Glass Particles Prompts Recall of Octreotide Acetate Injection

Syringe and Vials To date, the Company has not received any reports of adverse reactions related to this recall. Mylan Institutional LLC, a Viatris Company, has voluntarily recalled 1 lot of ...
ascopubs.org

Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC CTG MA.14

Management of Hot Flashes in Patients Who Have Breast Cancer With Venlafaxine and Clonidine: A Randomized, Double-Blind, Placebo-Controlled Trial Postmenopausal women who had surgical removal of ...
FierceBiotech

PRESS RELEASE: Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial

Company Plans to Initiate Phase III Program in First Half of 2008 LEXINGTON, Mass., Nov. 28 -- Indevus Pharmaceuticals, Inc. today announced positive results from its Phase II octreotide implant trial ...
Science Daily

No Benefit For Liver Cancer Patients From Long-acting Octreotide

Long-acting octreotide does not improve outcomes for patients with liver cancer compared to a placebo, according to the results of a new double blind study published in the January 2007 issue of ...
FiercePharma

Glide Appoints Albany Molecular Research for Manufacture of Novel Octreotide Solid Dose Formulation Clinical Trial Product

Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines and non-invasive diagnostics, today announced that it has appointed Albany Molecular ...